How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

59,638 results for

HIV Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

55661. Improving HIV Prevention Skills in People With Serious Mental Illnesses

focuses on behavioral skills training, with an emphasis on negotiating and communicating with prospective partners. Training includes information about HIV risk, including mechanisms of transmission, abstinence, and safer sex and drug use behaviors; HIV risk reduction strategies, including condom use, abstinence/safer sex negotiation skills, and reduced/safer drug use; and an opportunity to be tested for HIV if the participant has not already done so. The SB plus MI intervention (SB-MI) includes (...) components of the SB intervention, as well as elements of MI. MI includes identifying high risk sexual and drug use behaviors related to HIV; reducing the ambivalence about making high risk behavior changes; increasing motivation to change high risk behaviors; and developing a plan to implement these changes. HIV testing may be included. Participants in both interventions report to the study site on six to seven occasions over the course of the study. The visits last between 1 and 2 hours and include

2006 Clinical Trials

55662. Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

regimens may not be ideal in resource-limited settings, where viral load and resistance testing may not be readily available. The purpose of this study is to evaluate the safety and efficacy of the PI LPV/r alone in treatment-experienced, PI-naive HIV infected individuals who are experiencing virologic failure on three-drug regimens. This study will last 104 weeks. All participants will receive LPV/r twice daily for up to 104 weeks. Participants who experience virologic failure will receive (...) Experienced Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir Tenofovir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2006 Clinical Trials

55663. Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa

and adults will be randomly selected from the township population to determine the prevalence of active TB and the prevalence of HIV infection in this group of people. Fieldworkers will identify eligible participants in the township and will ask them to visit the clinic that day or the next. At the clinic, participants will be asked to complete a demographics and TB history questionnaire and provide a saliva sample for anonymous HIV testing. A sputum sample will be collected from each participant (...) people in the Masiphumelele Township. This assessment will include examining the diversity of TB strains in this population and determining the relationship between recurrent cases of TB and HIV infection. All sputum samples indicating TB infections that were previously collected from participants will undergo genetic testing by restriction fragment length polymorphism (RFLP) analysis. Participants will be asked to complete a demographics and TB history questionnaire and provide a saliva sample

2006 Clinical Trials

55664. Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, China

will undergo a pregnancy test. All participants will return to the clinic to receive their laboratory results and post-test counseling at a follow-up visit occurring approximately 2 weeks after their screening/enrollment visit. Any participant with a CD4 count less than 200 cells/mm3 or meeting other China Comprehensive AIDS Response (CARES) treatment criteria will be referred for further evaluation and care. HIV infected FBD participants with a CD4 count of 200 cells/mm3 or more will be invited to enroll (...) -Probability Sample Study Population Community sample of HIV infected and uninfected blood donors Criteria Inclusion Criteria for Stage I HIV Infected FBDs: Self-reported history of blood donation in 1995 or before HIV-1 infected ART naive Willing to provide locator information Willing to use acceptable forms of contraception Inclusion Criteria for Stage I HIV Uninfected Controls: HIV uninfected Willing to provide locator information Willing to undergo repeat HIV testing Inclusion Criteria for Stage II

2006 Clinical Trials

55665. Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer

and partial), progression-free survival, relapse-free survival, colostomy-free survival, overall survival, quality of life, and overall toxicity in patients treated with this regimen. Secondary Characterize the effect of this regimen on the underlying HIV condition by describing changes in viral load, CD4 counts, and the incidence of opportunistic illnesses, including the development of AIDS during and in the first year after treatment. Evaluate the effect of this regimen on anogenital human papilloma (...) during and for 1 year after completion of study treatment Anogenital Human Papilloma Virus (HPV) Infection and Anal Cytology [ Time Frame: 6 months following treatment discontinuation ] Objective Response Rate (Complete and Partial) [ Time Frame: 3 years following treatment discontinuation ] Number of participants with complete and partial responses based on the RECIST criteria Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study

2006 Clinical Trials

55666. SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Adult patients (over 18 years of age) of any ethnic group without restricted legal competence and who are capable of following the study instructions HIV-1 infection documented by confirmed positive HIV-1 antibody test and/or positive PCR for HIV-1 RNA Stable (no interruption or change of regimen in last 3 months) AZT-and 3TC-containing regimen > 3 months (...) No documented prior virologic failure (virological failure defined as 2 consecutive measurements 4 weeks apart with viral load of HIV-RNA > 400 copies/mL while on ART) CD4+ counts > 50 cells/µL Viral load < 50 copies/mL Karnofsky performance status ≥ 80% For women with childbearing potential, negative urine pregnancy test at Screening visit Exclusion Criteria: Serum phosphate level < 0.65 mmol/L Documented active opportunistic infections Subjects with previously documented K65R, 69S mutations or 3 or more

2006 Clinical Trials

55667. SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Tenofovir Lamivudine Emtricitabine Zidovudine Lamivudine, zidovudine drug combination Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors (...) information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients of either sex aged > 18 years. HIV positive. Stable antiretroviral therapy consisting of efavirenz (EFV) given with Combivir® or zidovudine (AZT) + lamivudine (3TC) for at least 6 months. Patients with viral loads < 50 copies/ml on last 2 consecutive tests and < 400 copies/ml for > 3 months. Patients requiring a lipid lowering agent

2006 Clinical Trials

55668. Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

: June 14, 2011 Last Update Posted: June 14, 2011 Last Verified: May 2011 Keywords provided by NeurogesX: Analgesics Capsaicin Neuropathic pain Neuropathy Distal sensory polyneuropathy Peripheral neuropathy Dermal assessment Pain measurement Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Nervous System Diseases Peripheral Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually (...) Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of NGX

2006 Clinical Trials

55669. Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus

Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00321438 Recruitment Status : Terminated First Posted : May 3, 2006 Last Update Posted : May 18, 2009 Sponsor: GlaxoSmithKline Information provided

2006 Clinical Trials

55670. Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

as negative glucose, negative or trace protein, and no clinically significant blood in the urine. Negative Food and Drug Administration (FDA)-approved HIV blood test. Negative hepatitis B surface antigen. Negative anti-HCV (hepatitis C virus antibody) and negative HCV PCR. Female-Specific Criteria: Negative beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential. A female participant must meet any of the following (...) Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: This study will test whether a vaccination schedule of experimental HIV vaccines is safe and whether it causes side effects in healthy adult volunteers. It will also compare the effects of vaccine injected into the muscle (intramuscular), just under the skin (subcutaneous), or into the skin (intradermal) and will monitor the social impact of being in an HIV vaccine study. Healthy volunteers 18-50 years old may

2006 Clinical Trials

55671. A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

efavirenz, in combination with TRUVADA, as a therapy for Human Immunodeficiency Virus (HIV)-infected patients not previously treated. Condition or disease Intervention/treatment Phase HIV Infections Drug: MK-0518 Drug: Comparator: efavirenz Drug: Comparator: Truvada Drug: Comparator: Placebo to MK-0518 Drug: Comparator: Placebo to efavirenz Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 566 participants Allocation (...) Measures : Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 [ Time Frame: 48 Weeks ] Antiretroviral activity was evaluated for participants who achieved HIV RNA level <50 copies/mL at Week 48. Number of Participants With Clinical Adverse Experiences (CAEs) at Week 48 [ Time Frame: 48 Weeks ] An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally

2006 Clinical Trials

55672. Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63

will also be undertaken. Condition or disease Intervention/treatment Phase HIV Infections Biological: Human Immunodeficiency Virus glycoprotein 140 (vaccine) Biological: HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant Biological: Labile Toxin mutant LTK63 adjuvant Phase 1 Detailed Description: The purpose of this study is to determine whether an HIV vaccine given as three nasal immunisations with a protein from HIV virus mixed with a toxoid adjuvant, followed by two intramuscular immunisations (...) Active Comparator: 2 Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant Biological: HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally Active Comparator: 3 Labile Toxin mutant LTK63 adjuvant Biological: Labile Toxin mutant LTK63 adjuvant Labile Toxin mutant LTK63 adjuvant alone Outcome Measures Go to Primary Outcome Measures : To determine the frequency

2006 Clinical Trials

55673. Reducing Unsafe Alcohol Use in HIV-Positive Individuals

Posted: September 4, 2006 Last Update Posted: October 30, 2015 Last Verified: October 2015 Keywords provided by Deborah Hasin, Columbia University: Unsafe drinking Human Immunodeficiency Virus Motivational Interviewing Additional relevant MeSH terms: Layout table for MeSH terms Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders (...) Study Details Study Description Go to Brief Summary: The main aim of this study is to test an intervention to reduce unsafe drinking among HIV-positive primary care patients. The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system). Subjects who receive the enhanced motivational interview are expected to show greater improvements in drinking than individuals

2006 Clinical Trials

55674. HIV Risk Reduction and Drug Abuse Treatment in Malaysia

) for recently detoxified and currently abstinent heroin dependent patients (N=180) in Malaysia (Specific Aim 1). The study will allow evaluation of 3 hypotheses: DC-HIV plus naltrexone is superior to DC-HIV alone; DC-HIV plus buprenorphine is superior to DC-HIV alone; and DC-HIV plus naltrexone is superior to DC-HIV plus buprenorphine. Primary outcome measures, assessed by 3x/wk urine toxicology testing and self-report, include resumption of heroin use, 1 or 3 weeks continuous relapse and reductions in HIV (...) HIV Risk Reduction and Drug Abuse Treatment in Malaysia HIV Risk Reduction and Drug Abuse Treatment in Malaysia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HIV Risk Reduction and Drug Abuse Treatment

2006 Clinical Trials

55675. Use of OraQuick for Screening HIV in Children Less Than Eighteen Months Old

/treatment HIV Antibody Testing Other: Abbott-rapid HIV antibody test Other: OraQuick Rapid HIV-1/2 Antibody test Detailed Description: BACKGROUND Serological identification of antibodies to Human Immunodeficiency virus (HIV) in blood is the most widely used method to screen for HIV infection. Use of oral fluid as an alternative to blood sample has been studies the past 20 years and extremely sensitive tests that are able to detect the very low quantities of antibodies found in oral fluid have been (...) and Prevention Information provided by: Thrasher Research Fund Study Details Study Description Go to Brief Summary: Blood is the most commonly used specimen to test for HIV. In the past 20 years, use of saliva as an alternative specimen for HIV testing has been explored. Today, very sensitive tests have been formulated and have been used for diagnosing HIV in adults and older children. OraQuick, a rapid test, is one such example. It is a devise that can be used to collect as well test the saliva. Most

2006 Clinical Trials

55676. Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

Sciences More Information Go to Additional Information: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: John Flaherty, Director, Medical Affairs, Gilead Sciences ClinicalTrials.gov Identifier: Other Study ID Numbers: AI266073 First Posted: August 17, 2006 Last Update Posted: April 10, 2008 Last Verified: April 2008 Keywords provided by Gilead Sciences: HIV HIV-1 AIDS Human Immunodeficiency Virus (...) Virological Suppression on Their HAART Regimen Study Start Date : July 2006 Actual Primary Completion Date : October 2007 Actual Study Completion Date : January 2008 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : Primary: Proportion of patients with HIV-1 RNA levels <200 copies/mL at Week 48 Safety Outcome Measures: Adverse Events, Laboratory Tests Outcomes Research Measures: Quality

2006 Clinical Trials

55677. Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients

Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Lopinavir Nevirapine HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid (...) Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2006 Clinical Trials

55678. A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia

that approximately 30% of reproductive age women in Lusaka are HIV-infected. Since voluntary HIV counseling and testing is not yet universally available in many of the district clinics, women receive all different types of contraception regardless of their HIV status. There is some observational data published recently that suggests hormonal contraception may increase HIV viral load in the female genital tract and potentially increase HIV transmission to the male partner. By contrast, barrier methods have (...) : University of Alabama at Birmingham ClinicalTrials.gov Identifier: Other Study ID Numbers: EGPAF PG-51161 First Posted: June 13, 2006 Last Update Posted: March 6, 2015 Last Verified: August 2009 Keywords provided by University of Alabama at Birmingham: Contraception Women HIV/AIDS IUD IUCD Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted

2006 Clinical Trials

55679. Adolescent Drug and HIV Prevention in South Africa

State University Study Details Study Description Go to Brief Summary: The purpose of this trial is to test the effectiveness of a classroom-based prevention program (HealthWise: Learning Life Skills for Young Adults) to reduce the risk of HIV/AIDS and STIs, as well as substance use, among adolescents in one area of South Africa. Condition or disease Intervention/treatment Phase Substance-Related Disorders Sexually Transmitted Diseases Behavioral: HealthWise South Africa curriculum Phase 2 Phase 3 (...) Adolescent Drug and HIV Prevention in South Africa Adolescent Drug and HIV Prevention in South Africa - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adolescent Drug and HIV Prevention in South Africa

2006 Clinical Trials

55680. Leukapheresis to Obtain Lymphocytes for Studies on Antiretroviral Naive HIV-infected Patients

-specific and innate immune responses including characterization of soluble factors associated with primary HIV infection. Condition or disease Intervention/treatment Human Immunodeficiency Virus Procedure: leukapheresis Detailed Description: Primary HIV-1 infected and chronically infected individuals will be recruited and leukapheresis will be performed. This one year study requires that patients be apheresed once before initiating therapy and on two other occasions (at month 6 and month 12) after (...) Update Posted: June 5, 2012 Last Verified: June 2012 Keywords provided by Canadian Immunodeficiency Research Collaborative: primary HIV infection chronic HIV infection Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>